<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4477">
  <stage>Registered</stage>
  <submitdate>6/06/2014</submitdate>
  <approvaldate>6/06/2014</approvaldate>
  <nctid>NCT02159729</nctid>
  <trial_identification>
    <studytitle>Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101</studytitle>
    <scientifictitle>Long-term Follow-up Study of Subjects Who Completed Kythera-sponsored Trials of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ATX-101-08-12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Submental Fat</healthcondition>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - ATX-101 (1 mg/cm2)
Treatment: drugs - ATX-101 (2 mg/cm2)
Treatment: drugs - ATX-101 (4 mg/cm2)

Placebo Comparator: Placebo - Subjects treated with placebo in previous ATX-101 studies

Experimental: ATX-101 (1 mg/cm2) - Subjects treated with ATX-101 (1 mg/cm2) in previous phase 2 studies

Experimental: ATX-101 (2 mg/cm2) - Subjects treated with ATX-101 (2 mg/cm2) in previous phase 2 studies

Experimental: ATX-101 (4 mg/cm2) - Subjects treated with ATX-101 (4 mg/cm2) in previous phase 2 studies


Treatment: drugs: Placebo
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

Treatment: drugs: ATX-101 (1 mg/cm2)
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

Treatment: drugs: ATX-101 (2 mg/cm2)
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

Treatment: drugs: ATX-101 (4 mg/cm2)
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as assessed by number of adverse events</outcome>
      <timepoint>up to 60 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy assessments using a clinician rating scale</outcome>
      <timepoint>up to 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy assessments using patient reported scales</outcome>
      <timepoint>up to 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy assessments using a laxity scale</outcome>
      <timepoint>up to 60 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Any subject who successfully completed a Kythera-sponsored clinical trial of ATX-101
             (06-03, 07-07, 09-15)

          -  Signed informed consent

          -  Willingness to comply with schedule and procedures of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Subjects who have had or are undergoing treatment that may affect the evaluation of
             the submental area will be excluded</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>205</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Mei-Heng Tan - Sydney</hospital>
    <hospital>Skin Centre, AHC House - Benowa</hospital>
    <hospital>Southeast Dermatology Belmont Specialist Centre - Carina Heights</hospital>
    <hospital>T/AS Dermatology Institute of Victoria - South Yarra</hospital>
    <postcode>2000 - Sydney</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode>4152 - Carina Heights</postcode>
    <postcode>3141 - South Yarra</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Kythera Biopharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Long-term follow-up study of subjects who completed Kythera-sponsored trials of ATX-101
      (06-03, 07-07, 09-15)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02159729</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Frederick Beddingfield, III, MD, PhD</name>
      <address>Sponsor GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>